The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looks like US likes INDV, it is up 24% now,excellent
Sadly but inevitably the only way forward for iNDV to reach its full potential and achieve full shareholder value is to make the companies listing primarily in the USA, massive unjustified divide between the two bourses, UK Plc being kept/played artificially low to enable potential US takeovers at ridiculously low levels just look at the likes of BT, VOD LLOY etc etc great businesses but on the wrong bourse imo I for one will be giving it the thumbs up when asked to vote on the switch, lovely rise today which I expected after Tuesdays shenanigans just proves my point
All pharma has endless stream of litigation.
Worst case if multiple never goes up, they can keep buying cheap shares.
Well must admit those numbers far exceeded my expectations…
Was hopeful, but too many times there has been a dampener put on the reports, not this time..
It looks looks like a strong buy until you read note 13 re. legal proceedings. It'll never trade at a decent multiple given the seemingly endless stream of litigation... Nevertheless, a nice trade this morning and good luck to those who hold for the US listing...
Cracking average I'm at 8.18
INDV continues to storm ahead despite increased competition. The SP was far too low so today's price increase is just partial catch-up. The switch to US main listing is a good move & will generate a lot more interest from US based investors. The big questions are how much longer will INDV remain independent before big PHARMA swallows it and at what price? To answer my own questions, not that long & North of £25.
Looking forward;
FY 2024
Net Revenue (NR)1
$1,240m to $1,330m
(+18% at midpoint vs. FY 2023)
Yes, very nice. 17% up shortly after opening.
Another USD100m buyback and 18% net revenue guidance for 2024. Would like a dividend quite soon.
Very glad I topped up at £11.68 in December and £12.21 in January, taking my average up to £7.35.
Hopefully back up to the £20 mark
Woo hoo!
Indivior Announces Q4 / FY 2023 Financial Results – Company Announcement
Bumper results and exceptional growth, should see a nice sp rally now.
Th erns is usually the day following purchase, save for Friday which appears on the Monday.
The share buyback has been ongoing for a while, as pointed out by TC. They did one previously and also had, from memory a share consolidation. The shares are purchased off four exchanges. The shares are literally wiped out and not kept in the treasury for the staff. It has, in theory, the effect of enlarging the eps and the sp. My thoughts are that we are in effect below the sp prior to share consolidation but we have had a litigation hit or two along with some money going out. Results tomorrow. I hope the buyback continues.
Indivior PLC announces an Equity Buyback for 13,631,504 shares, for $100 million. Indivior PLC (LSE:INDV) announces a share repurchase program. Under the program, the company will repurchase up to 13,631,504 shares for $100 million worth of shares. The purpose of the program is to reduce share capital of the company. (17 Nov 2023).
Anyone care to opine re the following as it appears the vol. is reflected in the share count in the US today. INDIVIOR PLC ("Indivior") announces that on February 20, 2024, it purchased for cancellation the following number of its ordinary shares of $0.50 each through Morgan Stanley & Co. International Plc.
Ordinary Shares
Date of purchases:
February 20, 2024
Number of ordinary shares purchased:
33,635
Highest Price per share:
1,350.00
Lowest Price per share:
1,322.00
Volume Weighted Average Price per share:
1,334.32
Nearly a 9% drop in the last few days. Is this in preparation of the results? Hope not.
Share price has just taken off to 1431p with a massive 334k buy at 13:33hrs. Nice jump!
No doubt loading up before results in 10 days - 22 February 2024.
Could see 1600p+ post results.
Thank you for sharing. I think the misleading prescription data + the larger than expected legal settlement are what’s keeping us down here.
Indivior has issues but it’s still too cheap, says BlackRock Throgmorton
BlackRock manager Dan Whitestone believes Indivior (INDV) shares are too cheap despite legal and competition concerns.
Whitestone holds the pharmaceutical group, which specialises in opioid addiction treatments, in his £584m BlackRock Throgmorton (THRG) closed-ended investment trust.
The shares in the group have been weak recently following the slightly higher cost of settling the bulk of its outstanding legal issues.
‘With continued strong trading in the core and regulatory risk in the rear-view mirror, we are frustrated by the performance of the shares which have been impacted by a few factors in recent months,’ said Whitestone.
This includes ‘a poorly-explained acquisition’ that saw it insource some manufacturing, ‘some higher-than expected selling general, and administrative costs’, and the launch of a competitor product and some weaker prescription data.
‘The first two we are less concerned about and think represents management sensibly investing some of the earnings beats into strengthening the business,’ said Whitestone.
‘We are keeping a closer eye on the prescription data and the competitor and have discussed both at length with management.’
The shares, which were at £13.74 on Monday, are ‘too cheap’, the manager added, pointing out they are trading at under 10x price/earnings and a double-digit percentage of its market cap is in net cash.
(P.S. Holding this time for £18.00. Not bothered if it takes 6-12 months . I admit I sold at the wrong time previously. Yes frustrating!).
Balyasny seems to have reduced short to 0.39% on 23 jan 2024
Don’t blame the lawyers. Blame the clients! Anyway, yes, huge potential. This has been a rollercoaster ride, and it’s been coasting down for far too long. Just needed a little momentum the other way. The positives here have been disregarded for too long. Well overdue a serious rerate. I’ve been here for some time. Was my rocket ship for quite some time. Has stalled a bit, but all the fundamentals are there to get us back into orbit.
This is my top pick this year. Single digit PE, buckets of cash and more than a shadow of litigation.
Good luck to addicts proving they got gum disease from INDV and not what got them there in the first place. How many of these have regular dental records. Exactly. Don't blame the lawyers for trying, this has been a punch bag for a long time but they should be okay this time.
What is the biggest killer in the US today of 18 to 45 year olds? Fentanyl. https://www.getsmartaboutdrugs.gov/media/dea-administrator-record-fentanyl-overdose-deaths
It is very sad, but this is indeed a growth industry and a growth stock on a single digit PE.
For all the bluster about Covid and huge amounts of money thrown at the problem, drug related deaths are and were significantly greater today and through the worst Covid years
Don't be frightened of the lawyers, scumbags indeed but just making a living like the Fentanyl dealers.
Still certain corners of the press (and shorts) pose INDV as the bad guy!
Truth will out.
Not only today ,started on 19/01/24 and more to come
Would love to know - don't see any specific news.
Cant help but feel that once legal issues have been squared away - the SP should fly.